SCHEMBL25529249

SCHEMBL25529249

Cc1c(-c2ccsc2)c(=O)c(C(=O)O)c2n1CCOC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 3/20 0.35
KDM4E B2RXH2 2/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
RIPK1 Q13546 1/20 0.33
ALOX5 P09917 1/20 0.33
PTGS1 P23219 1/20 0.33
PIK3CA P42336 2/20 0.32
PIK3CB P42338 2/20 0.32
PIK3CG P48736 1/20 0.32
GPR35 Q9HC97 1/20 0.32
AR P10275 1/20 0.32
WNT3A P56704 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
GAA P10253 1/20 0.31
BRD4 O60885 1/20 0.31
PIK3CD O00329 1/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30174224 0.90 CSNK1E (0.36) PRKDCKDM4EMKNK1MKNK2RIPK1
SCHEMBL25529263 0.82 PIK3C3 (0.32) KDM4EMKNK1MKNK2RIPK1KCNK3
SCHEMBL25529260 0.81 SMN1; SMN2 (0.36) PRKDCKDM4EKCNK3
SCHEMBL25529262 0.79 GRIN2B (0.33) KDM4EMEN1KMT2AKCNK3
SCHEMBL25529258 0.77 L3MBTL1 (0.36) PRKDCKDM4EALOX5PTGS1MEN1
SCHEMBL25529254 0.76 RIPK1 (0.38) PRKDCMKNK1MKNK2RIPK1PIK3CA
SCHEMBL27218043 0.75 HDAC3 (0.31) KDM4E
SCHEMBL27218052 0.74 PSMB5 (0.31) ACMSD
SCHEMBL30174219 0.72 CSNK1E (0.34) RIPK1
SCHEMBL30174238 0.71 TSHR (0.38) PRKDCKDM4ERIPK1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
CN-115605478-A Compounds and methods of use 埃克塞里艾克西斯公司(US) 2023-01-13 CN disclosed
EP-4110779-A1 COMPOUNDS AND METHODS OF USE Exelixis, Inc. (US) 2023-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX PRKDC 5/4885KDM4E 3309/4885MKNK1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.